Correlates of Protection Against Respiratory Syncytial Virus Infection in Infancy

Abu-Raya, Bahaa; Reicherz, Frederic; Lavoie, Pascal

doi:10.1007/s12016-022-08948-8

Cited by 7 publications

(4 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The overall decline we saw in RSV titer in a population-based cohort from Germany [25] is also similar to other reports assessing changes resulting from the pandemic [39]. While antibodies towards the F protein have been shown to correlate well with neutralizing activity [30], correlates of protection remain unclear [40], as does the impact of 2022-2023 RSV season where a surge in cases was reported.…”

Section: Discussionsupporting

confidence: 87%

Development and validation of a respiratory syncytial virus multiplex immunoassay

Marsall,

Fandrich,

Griesbaum

et al. 2023

Preprint

View full text Add to dashboard Cite

Respiratory syncytial virus (RSV) is one of the leading causes of severe respiratory disease in infants and adults. RSV exists as two subtypes A and B, which co-circulate throughout the season, although one will usually become dominant. While vaccines and monoclonal thera-peutic antibodies either are or will shortly become available, correlates of protection remain unclear. For this purpose, we developed an RSV multiplex immunoassay that analyses anti-body titers towards the post-F, Nucleoprotein, and a diverse mix of G proteins. Technical and clinical validation showed outstanding performance, while methodological developments ena-bled identification of the subtype of previous infections through use of the diverse G proteins for approximately 50% of samples. As a proof of concept to show the suitability of the assay in serosurveillance studies, we then evaluated titer decay and age-dependent antibody re-sponses within population cohorts. Overall, the developed assay shows robust performance, is scaleable, provides additional information on infection subtype, and is therefore ideally suited to be used in future population cohort studies.

show abstract

Section: Discussionsupporting

confidence: 87%

Development and validation of a respiratory syncytial virus multiplex immunoassay

Marsall,

Fandrich,

Griesbaum

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…The overall decline we saw in RSV titer in a population-based cohort from Germany [ 25 ] is also similar to other reports assessing changes resulting from the pandemic [ 39 ]. While antibodies toward the F protein have been shown to correlate well with neutralizing activity [ 30 ], correlates of protection remain unclear [ 40 ], as does the impact of 2022–2023 RSV season where a surge in cases was reported.…”

Section: Discussionmentioning

confidence: 99%

Development and validation of a respiratory syncytial virus multiplex immunoassay

Marsall,

Fandrich,

Griesbaum

et al. 2024

Infection

View full text Add to dashboard Cite

Purpose Respiratory syncytial virus (RSV) is one of the leading causes of severe respiratory disease in infants and adults. While vaccines and monoclonal therapeutic antibodies either are or will shortly become available, correlates of protection remain unclear. For this purpose, we developed an RSV multiplex immunoassay that analyses antibody titers toward the post-F, Nucleoprotein, and a diverse mix of G proteins. Methods A bead-based multiplex RSV immunoassay was developed, technically validated to standard FDA bioanalytical guidelines, and clinically validated using samples from human challenge studies. RSV antibody titers were then investigated in children aged under 2 and a population-based cohort. Results Technical and clinical validation showed outstanding performance, while methodological developments enabled identification of the subtype of previous infections through use of the diverse G proteins for approximately 50% of samples. As a proof of concept to show the suitability of the assay in serosurveillance studies, we then evaluated titer decay and age-dependent antibody responses within population cohorts. Conclusion Overall, the developed assay shows robust performance, is scalable, provides additional information on infection subtype, and is therefore ideally suited to be used in future population cohort studies.

show abstract

“…We assumed that palivizumab serum titers, or RSV neutralizing titers corresponding to palivizumab serum titers, equal or above 100 µ g / ml could avert (or at least postpone) RSV-related mortality. Although this threshold has been the best established correlation with protection to date [34] , [35] , [11] , studies that have investigated other immunological correlates of protections against severe RSV disease have yielded inconsistent findings [36] . As we use the protection threshold to predict the number of days protected, a lower or higher threshold would lead to a under- or overestimation of the number of days protected and therefore different impact estimates.…”

Section: Discussionmentioning

confidence: 99%

Maternal vaccination against RSV can substantially reduce childhood mortality in low-income and middle-income countries: A mathematical modeling study

Willemsen,

Borghans,

Bont

et al. 2023

Vaccine: X

View full text Add to dashboard Cite

Correlates of Protection Against Respiratory Syncytial Virus Infection in Infancy

Cited by 7 publications

References 42 publications

Development and validation of a respiratory syncytial virus multiplex immunoassay

Development and validation of a respiratory syncytial virus multiplex immunoassay

Development and validation of a respiratory syncytial virus multiplex immunoassay

Maternal vaccination against RSV can substantially reduce childhood mortality in low-income and middle-income countries: A mathematical modeling study

Contact Info

Product

Resources

About